Skip to main content
SKYE logo
SKYE
(NASDAQ)
Skye Bioscience, Inc.
$0.68-- (--)
Loading... - Market loading

Skye Bioscience (SKYE) Key Statistics & Financial Metrics

Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Market Cap26.98M
Enterprise Value19.14M

Price-Based Ratios

Valuation ratios based on stock price

Price/Book (mrq)2.99
Price/Tangible Book (mrq)2.99

Enterprise Value Ratios

EV-based valuation multiples

EV/Earnings-0.33
EV/EBITDA-0.34
EV/EBIT-0.34
EV/FCF-0.45

Stock Price

Current price, 52-week range, and moving averages

Current Price$0.68
1-Day Change-4.02%
52-Week High$5.75
52-Week Low$0.57
52-Week Change-84.00%
YTD Change-22.58%
1-Year Change-83.46%
50-Day MA$0.80
200-Day MA$1.25
Avg Volume (30 day)175.38K

Share Statistics

Outstanding shares, float, and per-share metrics

Shares Outstanding39.68M
Book Value per Share$0.23
Net Cash per Share$0.20
FCF per Share$-1.07

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Price Target$13.00
Target Upside/Downside1812.05%
Analyst ConsensusBuy
Analyst Count3

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Return on Investment Metrics

ROE, ROA, ROIC, and capital efficiency ratios

Return on Equity (ttm)-636.18%
Return on Assets (ttm)-295.27%
Return on Invested Capital (ttm)-3804.33%
Return on Capital Employed (ttm)-627.40%

Income Statement (TTM)

Trailing twelve months revenue and earnings

Revenue0.00
Gross Profit-172.89K
Operating Income-59.08M
Pretax Income-57.33M
Net Income-57.33M
EBITDA-56.61M
EBIT-56.54M
Diluted EPS$-1.45

Cash Flow (TTM)

Operating cash flow and free cash flow metrics

Operating Cash Flow-42.43M
Capital Expenditures6.00
Free Cash Flow-42.43M

Growth Rates (YoY)

Year-over-year growth metrics

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Assets & Cash

Total assets and cash positions

Total Assets (mrq)19.42M
Cash & Securities (mrq)8.15M
Net Cash (mrq)7.84M
Net Cash per Share$0.20

Debt & Liabilities

Liabilities, debt, equity, and working capital

Total Debt (mrq)311.32K
Working Capital (mrq)8.16M
Total Equity (mrq)9.01M
Book Value per Share$0.23

Liquidity & Leverage

Liquidity, leverage, and debt coverage ratios

Current Ratio (mrq)1.78
Quick Ratio (mrq)1.78
Debt/Equity (mrq)0.03

Dividend History & Payout Analysis

Dividend yield, payout ratios, and growth metrics

Dividend per Share (TTM)$0.00
Dividend Yield0.00%

Yield Metrics

Earnings, FCF, buyback, and shareholder yields

Earnings Yield-212.50%
FCF Yield-157.29%
Buyback Yield-0.08%
Total Shareholder Yield-0.08%

Financial Health Scores

Risk assessment and quality metrics

Altman Z-Score-49.38
Piotroski F-Score2/9

Frequently Asked Questions About Skye Bioscience Statistics

What are the key financial metrics for SKYE?

Skye Bioscience, Inc. (SKYE) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is SKYE's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Skye Bioscience is overvalued or undervalued.

How do I read SKYE's profitability ratios?

Skye Bioscience's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do SKYE's debt ratios indicate?

The financial health section shows Skye Bioscience's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is SKYE's dividend analysis?

The dividend section covers Skye Bioscience's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.